SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Big Sponsors > Roche

Samsung Biologics doubling capacity through third Korean plant

01-Dec-2015 - Samsung Biologics has invested $740m to build a third facility in Korea, adding a further 180,000L of mammalian cell culture capacity.

Catalent: Suspension at French plant likely due to human interference

17-Nov-2015 - Out-of-place softgel capsules have led to the suspension of manufacturing at a site in France, and Catalent says the problem is almost certainly due to malicious actions.

Roche: Small molecule exit will lead to outsourcing opportunities

16-Nov-2015 - Roche’s exit from four small molecule manufacturing plants will provide opportunities for third-party manufacturers, the firm says.

PEOPLE ON THE MOVE

The week in outsourcing appointments

28-Aug-2015 -

Roche expanding capacity 40% across network, but will still use CMOs

24-Jul-2015 - Roche is expanding its manufacturing operations to service its biologics pipeline, but the firm says it will continue to outsource approximately 20% of all production.

Environmental group welcomes DSM-Sinochem and GSK efforts to halt spread of antibiotic resistance

13-Jul-2015 - Antibiotic API makers have an obligation to ensure their activities do not spread resistance says a group that welcomed DSM-Sinochem’s commitment to environmentally-friendly production.

FDA offers guidance for running early-phase trials for gene, cell therapies

12-Jun-2015 - As the hype continues to hover around the promise of gene and cell therapies, the latest guidance from the FDA will help sponsors, CROs and investigators design early-phase clinical trials...

Antiquated clinical trial industry ripe for change from innovation, experts say

15-May-2015 - Experts across the sponsor-CRO spectrum seem to agree on at least one thing: the clinical trial process is ready for a major transformation, though how quickly and what types of...

Genentech makes cell line identification faster and cheaper

22-Apr-2015 - Genentech scientists have created a faster, cheaper way to identify cell lines, a boon for CMOs and preclinical researchers. 

Update

TransCelerate launches two new initiatives to accelerate clinical trials

10-Apr-2015 - Industry group TransCelerate BioPharma has established two new global initiatives around placebo and standard of care data sharing, and electronic labels for clinical trials – both of which aim to...

Does Europe’s Evotec offer an outsourcing model for the future?

24-Mar-2015 - With a small pipeline of clinical candidates, as well as R&D partnerships with top Big Pharma companies paying for those partnerships, Evotec could be in a position to re-define what...

Sigma-Aldrich lands exclusive distribution deal with Roche

19-Mar-2015 - Sigma-Aldrich has signed an exclusive agreement with Roche to distribute its biochemical reagents product portfolio via Sigma’s eCommerce and supply chain capabilities. The companies did not disclose any of the financial details...

Exclusive interview

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

05-Mar-2015 - Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told Outsourcing-pharma.com the preclinical CRO may add scale to US...

PPD’s X-Chem licenses cardiovascular drug discovery program to Bayer

19-Dec-2014 - PPD’s biotech company X-Chem has licensed a second drug discovery program to Bayer Pharma, which follows on a multi-target collaboration the companies established in 2012. 

Spoil sport: Pfizer teams up with WADA to combat drug cheats

04-Dec-2014 - Pfizer scientists wont have to run track, just share data to help catch sports cheats who use candidate drugs to enhance performance according to the World Anti-Doping Authority (WADA)....

Mabion extends agreement with Croatian CRO for Mabthera biosimilar study

01-Dec-2014 - The pace of recruitment is the biggest challenge in carrying out trials in Eastern Europe, says Mabion which has extended an agreement with local CRO Altiora for its biosimilar study.

Collaboration can fix ‘broken’ clinical trials model TransCelerate CEO tells CROs

18-Nov-2014 - Collaboration does not mean drugmakers have started playing nice, it’s just that the pain of shared problems has become unbearable according to TransCelerate Biopharma CEO, Dalvir Gill.

Catalent contract secure as Roche buys InterMune for $8.3bn

25-Aug-2014 - Roche has bought InterMune for $8.3bn (€6.3bn) and says it will continue contracts with Catalent and two API suppliers for the manufacture of its lead product Esbriet (pirfenidone).

Roche's oral octreotide pull-out no risk for Capsugel, says Chiasma

12-Aug-2014 - Chiasma says a scale-up manufacturing agreement with Capsugel will be unaffected despite Roche pulling out of a commercialisation contract for its oral peptide drug octreotide acetate.

Pfizer, Roche join consortium of adaptive trial sponsors

05-Aug-2014 - Pfizer and Roche have joined a consortium of clinical trial sponsors that are looking to design and implement adaptive trial designs. The consortium was partly founded by CRO Icon’s new...

Roche: ‘If suppliers don’t open up their books, then we are done’

18-Jun-2014 - Drug raw materials suppliers have not recognised their potential value to biopharmaceutical customers according to Roche which has called for a transformation in the vendor relationship.

Tamiflu spat: Roche ‘disingenuous,’ say review authors

10-Apr-2014 - Roche has clashed with the authors of a report slamming the efficacy of Tamiflu, each claiming the other’s analysis of patient data is seriously flawed.

DISPATCHES FROM GPCM

Roche: Governance of CMOs Ensures Sterility, Strengthens Partnerships

27-Jun-2013 - Roche says its hands on approach to managing sterile manufacturing partners is resulting in a safer and tighter network.

Price of Life Tech Steady at $11B as Roche Joins Bidding War Set for April

25-Mar-2013 - Bidders for DNA-sequencing equipment maker Life Technologies may not have to pay too much more than its current market value of $64 per share, or about $11B, according to an...

Key Industry Events